Jordan McPherson, Pharm.D., M.S., BCOP
Three key tips to help facilitate more timely care collaboration for cancer patients with immune-related adverse events.
Paul M. Szumita, Pharm.D., BCPS, BCCCP, FASHP, FCCM
Evidence-based guidance in the management of hospitalized patients with COVID-19 with a focus on immunomodulators
Jeffrey C. Pearson, Pharm.D., BCIDP
Summary of remdesivir for the treatment of COVID-19, as well as other promising antivirals in the pipeline.
John Fanikos, R.Ph., MBA
Take a stroll through history exploring the therapeutic options for VTE prophylaxis in medically ill patients
Jason R. Vilar, Pharm.D., BCCCP
A discussion of standard and alternative laboratory methods to measure levels of direct-acting oral anticoagulants
Zachary Stacy, Pharm.D., M.S., FCCP, BCPS
While peripheral arterial disease affects more than 8 million U.S. patients with the potential for significant cardiovascular complications and death, disease state awareness remains low.
James S. Kalus, Pharm.D., FASHP
A discussion of the complexities of re-initiating anticoagulants after a bleeding event caused by anticoagulants
Rachel C. Wolfe, Pharm.D., M.H.A., BCCCP
Pharmacists are well positioned to advocate for safe management of patients undergoing neuromuscular blockade and reversal and should expand their knowledge on this topic.
Kelly R. Reveles, Pharm.D., Ph.D., BCPS
Probiotics may help prevent C. difficile infections, but limitations exist and newer microbiome-targeted therapies offer advantages
Anne J. Gonzales-Luna, Pharm.D., BCIDP
Prophylaxis is used to prevent a variety of infections but using antibiotics to prevent C. difficile infection may have the opposite effect.